1. Cell Biology
  2. Immunology and Inflammation

Robust T cell activation requires an eIF3-driven burst in T cell receptor translation

  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate  Is a corresponding author
  1. University of California, Berkeley, United States
  2. University of California, San Francisco, United States
  3. Gladstone-UCSF Institute of Genomic Immunology, United States
https://doi.org/10.7554/eLife.74272
Share this article
Cite this article
  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate
(2021)
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
eLife 10:e74272.
https://doi.org/10.7554/eLife.74272
  2. Download BibTeX
  3. Download .RIS

Abstract

Activation of T cells requires a rapid surge in cellular protein synthesis. However, the role of translation initiation in the early induction of specific genes remains unclear. Here we show human translation initiation factor eIF3 interacts with select immune system related mRNAs including those encoding the T cell receptor (TCR) subunits TCRA and TCRB. Binding of eIF3 to the TCRA and TCRB mRNA 3'-untranslated regions (3'-UTRs) depends on CD28 coreceptor signaling and regulates a burst in TCR translation required for robust T cell activation. Use of the TCRA or TCRB 3'-UTRs to control expression of an anti-CD19 chimeric antigen receptor (CAR) improves the ability of CAR-T cells to kill tumor cells in vitro. These results identify a new mechanism of eIF3-mediated translation control that can aid T cell engineering for immunotherapy applications.

Data availability

Sequencing data has been deposited in GEO (GSE191306).Code used to analyze the microscopy images is available on github at https://github.com/Llamero/TCR_colocalization_analysis-macro

The following data sets were generated

Article and author information

Author details

  1. Dasmanthie DeSilva

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Dasmanthie DeSilva, A provisional patent application has been filed on some of the work presented herein..

  2. Lucas Ferguson

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  3. Grant H Chin

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  4. Benjamin E Smith

    School of Optometry, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  5. Ryan A Apathy

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  6. Theodore L Roth

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Theodore L Roth, is a co-founder of Arsenal Therapeutics..

  7. Franziska Blaeschke

    Gladstone-UCSF Institute of Genomic Immunology, San Francisco, United States
    Competing interests
    No competing interests declared.

  8. Marek Kudla

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.

  9. Alexander Marson

    Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Alexander Marson, is a compensated co-founder, member of the boards of directors, and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. Was a compensated member of the scientific advisory board at PACT Pharma and was a compensated advisor to Juno Therapeutics. Owns stock in Arsenal Biosciences, Spotlight Therapeutics, PACT Pharma and Merck. A.M. has received fees from Vertex, Merck, Amgen, Trizell, Genentech, AlphaSights, Rupert Case Management and Bernstein. Is an investor in and informal advisor to Offline Ventures. The Marson lab has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem..

  10. Nicholas T Ingolia

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3395-1545

  11. Jamie HD Cate

    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    For correspondence
    j-h-doudna-cate@berkeley.edu
    Competing interests
    Jamie HD Cate, A provisional patent application has been filed on some of the work presented herein..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5965-7902

Funding

National Institutes of Health (R01-GM065050)

  • Dasmanthie DeSilva
  • Grant H Chin
  • Jamie HD Cate

Cancer Research Institute (N/A)

  • Alexander Marson

Chan Zuckerberg Initiative (N/A)

  • Ryan A Apathy
  • Theodore L Roth
  • Alexander Marson

Innovative Genomics Institute (N/A)

  • Ryan A Apathy
  • Theodore L Roth
  • Alexander Marson

Parker Institute for Cancer Immunotherapy (N/A)

  • Alexander Marson

Tang Prize for Biopharmaceutical Science (N/A)

  • Jamie HD Cate

Damon Runyon Cancer Research Foundation (DRR#37-15)

  • Nicholas T Ingolia

National Institutes of Health (DP2 CA195768)

  • Lucas Ferguson
  • Marek Kudla
  • Nicholas T Ingolia

National Institutes of Health (P30EY003176)

  • Benjamin E Smith

National Institutes of Health (S10 OD018174)

  • Dasmanthie DeSilva

Care-for-Rare Foundation (N/A)

  • Franziska Blaeschke

German Research Foundation (N/A)

  • Franziska Blaeschke

Burroughs Wellcome Fund (N/A)

  • Alexander Marson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, DeSilva et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,400
    views
  • 589
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dasmanthie DeSilva
  2. Lucas Ferguson
  3. Grant H Chin
  4. Benjamin E Smith
  5. Ryan A Apathy
  6. Theodore L Roth
  7. Franziska Blaeschke
  8. Marek Kudla
  9. Alexander Marson
  10. Nicholas T Ingolia
  11. Jamie HD Cate
(2021)
Robust T cell activation requires an eIF3-driven burst in T cell receptor translation
eLife 10:e74272.
https://doi.org/10.7554/eLife.74272

Share this article

https://doi.org/10.7554/eLife.74272

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    N6-methyladenosine in DNA promotes genome stability

    Brooke A Conti, Leo Novikov ... Mariano Oppikofer
    Research Article

    DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluorouracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry. METTL3 and 6mA were required for repair of lesions driven by additional base-damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.

    1. Cell Biology

    Stratification of enterochromaffin cells by single-cell expression analysis

    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology

    Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis

    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.